Overview ArriVent Biopharma (https://arrivent.com/) is a clinical-stage biotechnology company based in Newtown Square, PA with 42 employees (Sep, 2023) developing targeted oncology therapies. The company was founded in 2021 with a $150 million Series A financing....
Exciting oncology research is underway at several emerging European biopharmaceutical firms. Advances in cancer immunotherapies, antibody-drug conjugates, and combination therapies are highlighted in recent disclosures from these companies targeting both solid tumors...
So far this year, Amplion has tracked 67 Seed and Series A investments into early-stage biotechs – down from 92 or a 27% decrease during the same period last year. That said, the biotech sector continues to witness rapid advancements, with numerous early-stage...
The emerging pharmaceutical industry plays a vital role in developing innovative treatments and therapies for various diseases. In 2023, several emerging pharmaceutical companies have made significant strides towards advancing their drug programs across a range of...
Advances in Cell Therapy in 2023: A Year of Promising Preclinical Studies Cell therapy has emerged as a groundbreaking field in medical science, offering innovative solutions for a range of diseases and conditions that were previously considered challenging to treat....
A number of emerging biopharma companies have announced significant funding rounds in recent months, as investors continue to bet on the potential of these early-stage firms to develop new therapies for a variety of diseases. Here are some of the top deals, along with...